Intravesical Immunotherapy of Superficial Bladder Cancer with Chitosan/Interleukin-12

Intravesical BCG has been used successfully to treat superficial bladder cancer for three decades. However, 20% to 30% of patients will fail initial BCG therapy and 30% to 50% of patients will develop recurrent tumors within 5 years. Alternative or complementary strategies for the management of supe...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer research (Chicago, Ill.) Ill.), 2009-08, Vol.69 (15), p.6192-6199
Hauptverfasser:	ZAHAROFF, David A, HOFFMAN, Benjamin S, HOOPER, H. Brooks, BENJAMIN, Compton J, KHURANA, Kiranpreet K, HANCE, Kenneth W, ROGERS, Connie J, PINTO, Peter A, SCHLOM, Jeffrey, GREINER, John W
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Intravesical Animals Antineoplastic agents BCG Vaccine - administration & dosage Biological and medical sciences Carcinoma, Transitional Cell - genetics Carcinoma, Transitional Cell - immunology Carcinoma, Transitional Cell - therapy Cell Line, Tumor Chitosan - administration & dosage Female Immunohistochemistry Interferon-gamma - blood Interferon-gamma - urine Interleukin-12 - administration & dosage Interleukin-12 - blood Interleukin-12 - urine Luciferases - biosynthesis Luciferases - genetics Macrophages - immunology Medical sciences Mice Mice, Inbred C57BL Nephrology. Urinary tract diseases Pharmacology. Drug treatments Transfection Tumors Tumors of the urinary system Urinary Bladder Neoplasms - genetics Urinary Bladder Neoplasms - immunology Urinary Bladder Neoplasms - therapy Urinary system involvement in other diseases. Miscellaneous Urinary tract. Prostate gland
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!